Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMIRAY: JNJ-90301900 + cCRT in Locally Advanced HNSCC
NCT07219212Phase 1Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Jan 2026
- Primary completion
- Jul 2028
- Modality
- Nanoparticles, Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of NBTXR3 in head and neck squamous cell carcinoma (HNSCC), sponsored by Johnson & Johnson. Primary endpoint: Adverse Events at 118 weeks. Started Jan 2026; status: recruiting.
02
Drugs
NBTXR3
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07219212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219212.